bit recent I'd very a talk highlights. about much, Eric. like to Thank you our operational Today, little
the had we're all, from cumulative than XXX,XXX was of we treatments more end First XXXX. as XXXX, up say delivered, the XX% which end pleased CytoSorb that of of of to
earlier as of CE which as when or MDR, either Devices device the we for effort Directive was medical December achieve known the under CytoSorb currently Medical Our also European extended EU XXXX is Mark Union MDD, certification, regulation ongoing.
new definitive these entered for We traded its the company, a Sciences with who including leadership to CytoSorb Formulations Life acquire it, with following of publicly and key personnel businesses, force nephrology Biologics temporary are ARISE Biocon into Branded Indian distribution and also in in agreement partnership pharmaceutical India. strategic with commercializing India Biocon's agreement the field CytoSorb unit Biocon's and
our is stand-alone importance of Also initiative. pump hemoperfusion
look. use. very it pump. testing unit, a And market, will this the how We've is who this infrastructure. not is pump GMBH picture blood and is feedback a in strong our very year. excited distribution excellent the hopefully, This Akeso expected near very easy to into dialysis to of the get be been out able September Our from beta our this launch its for our purified year capability new have bring stand-alone We're next-generation expiration that following Europe last this of agreement purification to future. to we're with countries users to in later expecting had do the of It's initiative pure-just-pump to pump have
Annual of in who are users, in annual cardiothoracic Moving the and and we're learn involved in Association data the conferences only surgery perfusionists attracts of for XX of to Toronto, meeting selected innovations other surgeons, health surgery the not on we're care world XX to The controlled randomized cardiothoracic about through prestigious in breakout clinical but workers presentation whole most cardiothoracic The new host pivotal the a cardiac at area surgery. Thoracic STAR-T and the trial, pleased to is a of trial. STAR-T one Surgery Canada. April say AATS being American held Meeting
the week of and that or day as presentation, Investor have esteemed same will a to the data with the by [ be presentation, likely Following thought the analysts plan Analyst meeting either This leader subsequent a ] not following and and panel. later we week. investors AATS this review but Day be an will provide it
our top the blood line our analysis second additional of polenta]. in ATR data to patients we DrugSorb that CABG in of approval reducing to Canada FDA for isolated thinner December, we've of the XXXX [ done regulatory announcement bleeding surgery undergoing now upon Health on the U.S. Based and of following plan in severity half submit with the idea
see you final where is line, tentative data a the is STAR-T estimate Here time analysis imminently. pending
late using of We data a in April. this CytoSorb analysis at of Europe [ analysis that Well, EuroPCR be love late-breaking coming remove Data expect conference in data STAR session have Europe at which the XXXX. for from presented from an in the AATS presented third the at registry, is May ] titers. in to the collection registry, the real-world application will to
the in FDA And this If half FDA based appropriate, ATR we'll FDA will before XX the be time line that well. to up setting process well, of it's potential DrugSorb published the get there, In Canada after in if FDA everything from Based also upon of will XXXX preparing the give goes days an upon submission, for as also out position a potentially the for from for from to year, to XX-month acceptance. and to and approval. of approval lines Health able we year. meantime, half to be of end FDA FDA will we Health about to -- obtain lines, this time notice time approval second submit formal hopefully second Canada be the submission to X-
numbers in we second has our the change see well, We changed presentation. [indiscernible] on market given isolated this approval in not to you that are the currently haven't the on of population on from slide, expect the represent XXXX. majority addressable that facing CABG And what opportunity, believe Canadian request clinical CABG our approval needing total begin investor will next on overwhelming patients focusing that and commercialization our much receiving after half isolated need. U.S. go things the significantly If can been
surgery urgent and U.S. of a Canada Brilinta CABG There's It emergent XX,XXX and initial $X,XXX leading market. about annually about million total represents $XXX addressable patients or about on device.
that PXYXX expect goes only both make on Brilinta States which inhibitor has of the advantage patent in Plavix, the on grow the this off which platelet the Brilinta market. likely reversible that would in in share the and ATR because been generic drop will major given is United market year, a DrugSorb We market prices, XXXX leading to also
market States twofold. and the Brilinta the Once that goes Canada the drug superior to to total share, market in price United by addressable away, expect helping we gain potentially differential expand
to turning update. sales XXXX. I release, the Now The highlights sales for our press over think, goes
sales core that number However, I out wanted a although few that grew things. One And relatively year-over-year. XX% to point modest. is is CytoSorb
our I seeing our think it masks certain sales have we excellent divisions. in -- some of been performance that
have sales a year. distributor $X sales our partner for the division, recall, and we saw sell we our in What [ XX% performance direct sell you growth we other We sales As sell countries they product million countries hybrid from own with to roughly or countries, accounting where XX of strong in and force, in XXXX for with a in XX% Germany. internationally direct we where XX again, international sales model direct division. our saw through other XX direct ]
same to to we actually in account world today. revenue we XXXX, as look period This countries the quarters around continue for sales the really sell Distributor XXXX to where the XX% first XX versus is distributor diversify sales. grew CytoSorb X partner including base U.S. our the not important in of
and our the and market, [ distribution agreement However, impacted the slipping because Nikes this pump hemoperfusion to made of into up hemoperfusion distribution decision bringing of ordering we agreement, expire favor to from that ] own orders distributor distributors the delay with in just pure the in wound change less pump, XXXX.
U.S. the for XX% growth sales And was or sales for year Germany sales distributor in including overall sales this, X%. of finally, year. X%, product the direct of grew not Because
market are costs fewer beds, terms staffing range in of additional aftermath patients, intensive by fewer fewer improved as revenue-generating hospitals XXXX, inflation, and staffing in care shortages, ICU also the including costs still driven well. has through weight high the feeling but moving a the ICU of unit, of energy the procedures COVID-XX significantly of Although
this procedures performed, sales and system. health State last product incentivizes we However, outlook XXXX, white we that paper payments that deemphasize the said, a payment result system it for Government funded. focused hope emphasized our recovery and issued as XXXX, laws more care. Governments That improved set care a begin hospital payments DRG in and revenue hospitals of Germany's quality are a known will significantly proposal to how seeing year. in through consensus are currently measures are for Germany that also July Federal sum In diagnosis-related XX% appropriate that represented a in we Germany Germany. and lump would tracking on treated new generation patients hospitals group the patient base change and could reform
while controlling the favor to a of ones critical such patients, focus the help hospitals in therapies that organ recover a deadly sicker clinical cost smaller surgery, and in patients outcomes severity longer an remaining operations cardiac reform into while is life-threatening our help hospital, business such cardiothoracic is to larger importantly, as and that believe the and care for keep patients of This of transplant conditions, reducing our and term. on consolidation improve support surgery illness favor life to reducing we the outpatient given of expensive routine on measures shift need of expected therapies goal operations faster, by the other procedures more the increased inflammation centers of and and that may reduce hospitals and complex
and take track years administrators to we with expect interest. such change to implement, Hospital time essentially and planning even look careful these developments will
you the U.S. contracts on to of million the the see the we by $XX have today. slide in and left-hand this here of grants products are government talk being other of nondilutive many And seen our funding. about actually before, extensive you X about and where technology commercialized tune that side, Now support
or that. wanted much don't today, We and to I focus on VetResQ. CytoSorb typically try we about do to talk But really too ECOS-XXXCY
I'd on what addition, each received products we've plasma thought right-hand program a give $XX our and just And today. a products a the doing one on of which side, million to of of the we're DoD to the development current In you funding is market. spend these grant for this for slide of I bring flavor development under products to universal HemoDefend-BGA
for is approved Union XXXCY ex in transplant. of for vivo European Speaking perfusion and organ the organ solid
the organ organ at availability temperature-controlled an being the is blood or substandard of would transplant but limited or suitable failure, of organs in otherwise organ advanced is discarded. fluid healthy EVOP, vivo is organs. and the transporting with treatment used Solid ones perfusion on Ex option functioning that nutrient-rich by as ICE increasingly main the be oxygenated improve organ as salvage otherwise alternative to transplanted to known
it -- we that an provide lower work mediators with life one of our inflammation by Aferetica you system. on vivo to organ plugs by core their to cartridge the ] PRSO can one machine system does label organ this into the per pioneers left-hand often seen reduce them EVOP. see been perioperatively. right and of the control private that called And ECOS-XXXCY perfusion here, has a However, in called is the the not within the [ that partners, inflammatory space. specifically is dysfunction EU-approved And side directly organ during ex
recondition inflammatory goals pool ECOS-XXXCY mediators. cited benefits normally reduces of transplant, functioning and it and primary in organs improve increasing of poorly data and rates in to clinical that the discarded, are to donor as well of data the outcomes. And It helping would helps graft been dysfunction, studies, early early be organs as to shown early particularly pigs has lung both in reduce in that human
On which is CytoSorb the animals. for essentially is next companion slide VetResQ,
COVID companion the pandemic has Now ownership. animal driven
XX% heat owning leptosperosis, according shock, of as households as and owning American a stroke, and companion cat medical U.S. others. of inseptic to such emergencies, the to wide from Society, XX% with a drug infections Veterinary Now dog trauma Medical animals intoxication, variety such approached ranging a
regional to CytoSorb of our animals had but companion pump in you of vents. of a veterinary to a in full-size centers, rescue we'll all-in-one XXXX, with a debut we range cartridges X brings sizes for treat XXXX, the successful That see that here. of and medicine hemoperfusion of includes number limited power launch the VetResQ to integrated intended solution And can that veterinary
anyone type universal need universal of that but last create And can the Hematin plasma, was developed which [indiscernible], in and is ] anti-B be least, blood not promise to type specific. by plasma holds and of plasma. regardless blood that off plasma shelf antibodies typing need, which blood removing given does to the make [ not anti-A
the on plasma. status see B, pools what A, can logistics Type you And O called stores which of off logistics a where today, shelf Type of of right-hand the banks universal Type plasma the have their But simplifies maintain that a could blood Type to and is current of type. to plasma those then to blood side plasma, AB simple here universal regardless patient given be unit
per life-saving Many plasma critical for purification States alone, of treatment trauma albumin XX,XXX applications isolation autoimmune more and In factors infectious component such units X.X daily IVIG year. critically hemophilia, and illness include are patients administered treatment plasma than as disease example, for fresh the or resuscitation, units clotting of disease. the for ill frozen United of million for of and
blood that U.S. world. plasma having Defense, our successfully that around every to anti-A independent and absorber human $XX of plasma, goal more off-the-shelf universal with plasma can from the anti-B the with in we with freeze-dried the a Department ambulance type antibodies and and again, plasma remove collaborate room have emergency And the one-size-fits-all freeze-dried developed universal of provided prototype provider demonstrated from [indiscernible] in has funding CytoSorb that million than
FDA This human to of commercialization. we've and goal big trials is [indiscernible] clinical now discussions and the with with opportunity a and recently met advancing preliminary
let Kathy? go that, to turn for So over me with highlights cover to financial back it Kathy and XXXX.
